Management of Hepatic Encephalopathy
|
|
- Roderick Hawkins
- 5 years ago
- Views:
Transcription
1 Management of Hepatic Encephalopathy Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology
2 Disclosure 1. The speaker Atif Zaman, MD MPH have no relevant financial relationships to disclose. 2. The speaker/planner Lauren Myers, MMSc, PA-C have no relevant financial relationships to disclose.
3 Hepatic Encephalopathy Discuss diagnosis and prognosis Nomenclature (minimal vs overt) Treatment options
4 Pathophysiology of Hepatic Encephalopathy Ammonia Upregulation of astrocytic peripheral benzodiazepine receptors (PBR) Neurosteroid production Modulation of GABA A receptor Hepatic encephalopathy
5 Hepatic Encephalopathy Is A Clinical Diagnosis Clinical findings and history important Ammonia levels are unreliable Measurement of ammonia not necessary Measurement of ammonia levels may be supportive when diagnosis is in doubt
6 Stages of Hepatic Encephalopathy Stage Mental state Neurologic signs 1 Mild confusion: limited attention Incoordination, tremor, span, irritability, inverted sleep impaired handwriting pattern 2 Drowsiness, personality changes, Asterixis, ataxia, dysarthria intermittent disorientation 3 Somnolent, gross disorientation, Hyperreflexia, muscle marked confusion, slurred speech rigidity, Babinski sign 4 Coma No response to pain, decerebrate posture
7 Minimal Hepatic Encephalopathy Occurs in 30-70% of cirrhotic patients without overt hepatic encephalopathy Detected by psychometric and neuropsychological testing May improve with lactulose or synbiotics (probiotics and fermentable fiber)
8 Treatment of Hepatic Encephalopathy Identify and treat precipitating factor Infection GI hemorrhage Prerenal azotemia Sedatives Constipation Protein restriction should be avoided
9 Treatment of Hepatic Encephalopathy Lactulose (adjust to 2-3 bowel movements/day) Long-term therapy assessment Higher likelihood of recurrent encephalopathy Assessment of need for liver transplantation
10 Current HE Treatment Options Drug Name Drug Class Indication Lactulose Rifaximin Neomycin Metronidazole Vancomycin Poorly absorbed disaccharide Non-aminoglycoside semi-synthetic, nonsystemic antibiotic Aminoglycoside antibiotic Synthetic antiprotozoal and antibacterial agent Aminoglycoside antibiotic Decrease blood ammonia concentration Prevention and treatment of portal-systemic encephalopathy Reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients 18 years of age. Adjuvant therapy in hepatic coma Ototoxicity and nephrotoxicity Not approved for HE Peripheral neurotoxicity Not approved for HE Bacterial resistance and renal toxicity Mullen KD et al. Semin Liver Dis. 2007;27(suppl 2):32-47.
11 Lactulose Currently the mainstay of therapy of HE; ~70% to 80% of patients with acute and chronic HE improve with lactulose treatment Administered orally, by mouth or through a nasogastric tube or via retention enemas Adjust to 2-3 bowel movements/day Principal side effects include abdominal distension, cramping, diarrhea, electrolyte changes, and flatulence Bajaj JS. Aliment Pharmacol Ther 2010;31:
12 Rifaximin Minimally absorbed (<0.4%) oral antibiotic No clinical drug interactions reported No dosing adjustment required in patients with liver disease or renal insufficiency In registration trials, 91% of patients were given lactulose concomitantly 58% reduction in risk of recurrent hepatic encephalopathy (NNT=4) 50% reduction in risk of hospitalizations (NNT=9) Bass NM et al. N Engl J Med. 2010;362:
13 Take Home Points Hepatic Encephalopathy Clinical diagnosis Identify precipitating factors Identify and then treat patients with recurrent encephalopathy
Treatment of Overt Hepatic Encephalopathy: Focus on Outpatient Management
Treatment of Overt Hepatic Encephalopathy: Focus on Outpatient Management Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation
More informationDiagnosis and Management of Hepatic Encephalopathy
Diagnosis and Management of Hepatic Encephalopathy Fred Poordad, MD VP, Academic and Clinical Affairs The Texas Liver Institute Professor of Medicine University of Texas Health Science Center San Antonio,
More informationThis educational website is funded by a grant from Norgine. Norgine has no responsibility for content or conduct of this website.
Date of preparation: February 2014. 4C/NIPV/0517 1 This educational website is funded by a grant from Norgine. Norgine has no responsibility for content or conduct of this website. 2 Disclaimer This educational
More informationThank you. for supporting this program. For additional CME offerings, please visit
Thank you for supporting this program For additional CME offerings, please visit www.chronicliverdisease.org Accredited by: Disease Burden Patient Discharges with Cirrhosis* Hospital Discharges Associated
More informationCIRRHOSIS Definition
Cirrhosis Update Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology Weill Cornell Medical College CIRRHOSIS Definition Irreversible fibrous
More informationManagement of Cirrhosis Related Complications
Management of Cirrhosis Related Complications Ke-Qin Hu, MD, FAASLD Professor of Clinical Medicine Director of Hepatology University of California, Irvine Disclosure I have no disclosure related to this
More informationThe Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:
The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatic Encephalopathy Hepatic Encephalopathy:
More informationProgram Disclosure. This program is supported by an educational grant from Salix Pharmaceuticals.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship
More informationProgram Disclosure. A maximum of 1.5 contact hours may be earned for successful completion of this activity.
Program Disclosure This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through
More informationAscites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology
Ascites Management Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH have no relevant
More informationCOMPLICATIONS OF CIRRHOSIS: ASCITES & HEPATIC ENCEPHALOPATHY
COMPLICATIONS OF CIRRHOSIS: ASCITES & HEPATIC ENCEPHALOPATHY DR. ESTER YAGUDAYEVA CLINICAL PHARMACIST HOSPICE PHARMACY SOLUTIONS OBJECTIVES Understand the prognosis of End Stage Liver Disease (ESLD) Identify
More informationNational Institute for Health and Clinical Excellence. Single Technology Appraisal (STA)
Comment 2: the draft scope Appendix D NICE s response to consultee and commentator comments on the draft scope and provisional matrix National Institute for Health and Clinical Excellence Single Technology
More informationConflict of Interest and Disclosures of Relevant Financial Relationships
Management of Hepatic Encephalopathy in Hospice and Palliative Care ProCare HospiceCare Lunch and Learn Series Brett Gillis, PharmD, RPh Conflict of Interest and Disclosures of Relevant Financial Relationships
More informationCauses of Liver Disease in US
Learning Objectives Updates in Outpatient Cirrhosis Management Jennifer Guy, MD MAS Director, Liver Cancer Program California Pacific Medical Center guyj@sutterhealth.org Review cirrhosis epidemiology,
More informationThe Importance of Diagnosing Covert Hepatic Encephalopathy
The Importance of Diagnosing Covert Hepatic Encephalopathy Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council
More informationIJBCP International Journal of Basic & Clinical Pharmacology
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20170331 Original Research Article Effectiveness
More informationHEPATIC ENCEPHALOPATHY(HE) AND NUTRITIONAL SUPPORT. Jin-Woo Lee, MD,PhD. Division of Hepatology Inha University Hospital
HEPATIC ENCEPHALOPATHY(HE) AND NUTRITIONAL SUPPORT Jin-Woo Lee, MD,PhD. Division of Hepatology Inha University Hospital Contents 1. Definition and causes of HE 2. Diagnosis and treatment of HE 3. Malnutriton
More informationHepatic Encephalopathy
Hepatic Encephalopathy John Barber UMassMedical Student, Class of 2019 www.12daysinmarch.com Outline Overview Normal Physiology Pathology Symptoms Diagnosis Treatment Overview Ammonia (NH 3 ) is a byproduct
More informationMANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT
MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT Sherona Bau, ACNP The Pfleger Liver Institute 200 UCLA Medical Plaza, Suite 214 Los Angeles, CA 90095 September 30, 2017 I
More informationMichael Tuchfarber, MD edition
Michael Tuchfarber, MD 2017 edition Review the possible mechanisms of the pathogenesis of hepatic encephalopathy Review the clinical manifestations of hepatic encephalopathy Understand how to make a diagnosis
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationFormulations and Availability 900 BILLION 5,319 HIGH POTENCY PROBIOTIC PEDIATRIC ADULT GERIATRIC PROVEN BY RESEARCH. HIGH-POTENCY. NO SHORTCUTS.
Formulations and Availability S TU D I E S PE R D I S E A S E 39 LIVER Liver Disease, Cirrhosis, Liver Failure, Hepatic Encephalopathy S TU D I E S PE R AG E G RO U P Visbiome Regular Product Code: 693-0412-01
More informationAnalysis of combined effect of synbiotic and LOLA in improving neuropsychometric function
2017; 6(5): 152-156 ISSN (E): 2277-7695 ISSN (P): 2349-8242 NAAS Rating 2017: 5.03 TPI 2017; 6(5): 152-156 2017 TPI www.thepharmajournal.com Received: 26-03-2017 Accepted: 27-04-2017 Preetha Nandabalan
More informationThe University Hospitals and Clinics The University of Mississippi Medical Center Jackson, Mississippi
The University Hospitals and Clinics The University of Mississippi Medical Center Jackson, Mississippi Pharmacy and Therapeutics Committee Drug Evaluation (Xifaxan ) June 2012 Generic Name Brand Name Xifaxan
More informationComplex neuropsychatric syndrome complicating advanced liver disease and/or portosystemic shunting (1990s) Complex neuropsychatric syndrome caused by
Complex neuropsychatric syndrome complicating advanced liver disease and/or portosystemic shunting (1990s) Complex neuropsychatric syndrome caused by portosystemic venous shunting with or without intrinsic
More informationDepartment of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX
ANTIBIOTICS FOR HEPATIC ENCEPHALOPATHY Role of Antibiotics in the Management of Hepatic Encephalopathy Willis C. Maddrey, MD Department of Internal Medicine, University of Texas Southwestern Medical Center
More informationCHAPTER 7. End Stage Liver Disease in the ICU: Walking a Tightrope. Lynn A. Kelso, MSN, APRN, FCCM, FAANP University of Kentucky College of Nursing
CHAPTER 7 End Stage Liver Disease in the ICU: Walking a Tightrope Lynn A. Kelso, MSN, APRN, FCCM, FAANP University of Kentucky College of Nursing Besey Oren, Assistant Professor Istanbul University Health
More informationXifaxan. Xifaxan (rifaximin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.34 Subject: Xifaxan Page: 1 of 6 Last Review Date: December 8, 2017 Xifaxan Description Xifaxan (rifaximin)
More informationDecompensated chronic liver disease
Decompensated chronic liver disease Definition of decompensated chronic liver disease Patients with chronic liver disease can present with acute decompensation due to various causes. The decompensation
More informationRIFAXAMIN VS LACTULOSE; IN IMPROVING CIRRHOTIC PATIENTS WITH HEPATIC ENCEPHALOPATHY
The Professional Medical Journal DOI: 10.17957/TPMJ/16.3347 ORIGINAL PROF-3347 1. MBBS, MD gastroenterology Assistant Professor of Gastroenterology Nawaz Sharif Medical College, University of Gujrat 2.
More informationREFERENCE NUMBER: NH.PMN.47 EFFECTIVE DATE: 11/11
PAGE: 1 of 5 RETIRED: REVIEWED: 11/11, 12/14, 08/16, 07/17 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough
More informationLiver failure &portal hypertension
Liver failure &portal hypertension Objectives: by the end of this lecture each student should be able to : Diagnose liver failure (acute or chronic) List the causes of acute liver failure Diagnose and
More informationComplications of Cirrhosis
Complications of Cirrhosis Causes of Cirrhosis Alcohol Chronic Viral Hepatitis (B/C) Haemochromatosis Autoimmune Hepatitis NAFLD/NASH Primary Biliary Cirrhosis Primary Sclerosing Cholangitis 1-AT deficiency
More informationDeveloped September Revised May 2018; June 2017; June 2015; October 2013; December 2011; April 2010; December 2006.
Texas Vendor Drug Program Drug Use Criteria: Rifaximin (Xifaxan ) Publication History Developed September 2006. Revised May 2018; June 2017; June 2015; October 2013; December 2011; April 2010; December
More informationCHAPTER 1. Alcoholic Liver Disease
CHAPTER 1 Alcoholic Liver Disease Major Lesions of Alcoholic Liver Disease Alcoholic fatty liver - >90% of binge and chronic drinkers Alcoholic hepatitis precursor of cirrhosis Alcoholic cirrhosis end
More informationClinical Policy: Rifaximin (Xifaxan) Reference Number: ERX.NPA.40 Effective Date:
Clinical Policy: (Xifaxan) Reference Number: ERX.NPA.40 Effective Date: 06.01.15 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationFaculty Affiliation. Faculty Disclosures. Alpesh Amin, MD, has no real or apparent conflicts of interest to report.
Strategies for Improving Long-term Management of Hepatic Encephalopathy: Assessing Therapies for Secondary Prophylaxis Sponsored by Integrity Continuing Education, Inc. Supported by an educational Practitioner
More informationHepatic Encephalopathy. An information guide
TO PROVIDE THE VERY BEST CARE FOR EACH PATIENT ON EVERY OCCASION Hepatic Encephalopathy An information guide Hepatic Encephalopathy What is Hepatic encephalopathy? Hepatic encephalopathy, also known as
More informationManagement of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL
Management of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL Terminology Acute decompensation of cirrhosis - stable patient with sudden deterioration Acute-on-chronic liver failure
More informationGuidelinesforNurses.co.uk/HE
cpd credits Summaries and resources to support best practice Management of hepatic encephalopathy in primary care Michelle Clayton (Chair), Dr Richard Aspinall, Dr Honor Merriman, Dr John O Malley This
More informationStrategies for Improving Long-term Management of Hepatic Encephalopathy: Assessing Therapies for Secondary Prophylaxis
Strategies for Improving Long-term Management of Hepatic Encephalopathy: Assessing Therapies for Secondary Prophylaxis Sponsored by Integrity Continuing Education, Inc. Supported by an educational Practitioner
More informationTHE LIVER AND THE GUT
THE LIVER AND THE GUT Liver & Gut A quintessential relationship One does not work well without the other There is a continuous bidirectional communication between these organs through the bile, hormones,
More informationEnd Stage Liver Disease Regional Audit Casenote Survey
1. This questionnaire is an audit of clinical documentation of patients who have died of end stage liver disease. If you have any questions about how this form should be completed please contact Dr Grace
More informationSlide 1 THE LIVER AND THE GUT. Slide 2 Liver & Gut. Slide 3 Gut Health For Detoxing
Slide 1 THE LIVER AND THE GUT Slide 2 Liver & Gut A quintessential relationship One does not work well without the other There is a continuous bidirectional communication between these organs through the
More informationManagement of the Cirrhotic Patient in the ICU
Management of the Cirrhotic Patient in the ICU Peter E. Morris, MD Professor & Chief, Pulmonary, Critical Care and Sleep Medicine University of Kentucky Conflict of Interest Funding US National Institutes
More informationRole of Branched Chain Amino Acids in Hepatic Encephalopathy
ORIGINAL ARTICLE (APMC 378) DOI: 10.29054/APMC/17.378 Role of Branched Chain Amino Acids in Hepatic Encephalopathy Umair Ahmed, Aamir Shaukat, Hooria Aamir, Awais Ahmed ABSTRACT Introduction: Hepatic encephalopathy
More informationHepatic Encephalopathy Update: Reports from the 64th Annual Meeting of the American Association for the Study of Liver Diseases
Hepatic Encephalopathy Update: Reports from the 64th Annual Meeting of the American Association for the Study of Liver Diseases Credit Designation Purdue University College of Pharmacy designates this
More informationMicrobiome GI Disorders
Microbiome GI Disorders Prof. Ram Dickman Neurogastroenterology Unit Rabin Medical Center Israel 1 Key Points Our gut microbiota Were to find them? Symbiosis or Why do we need them? Dysbiosis or when things
More informationA Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy
1458 ORIGINAL CONTRIBUTIONS nature publishing group see related editorial on page x A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of
More informationManagement of overt hepatic encephalopathy: a focus on rifaximin-α and NICE TA337
cpd credits summarising clinical guidelines for primary care Guidance Update www. Management of overt hepatic encephalopathy: a focus on rifaximin-α and NICE TA337 This Guidelines supplement has been commissioned
More informationFaculty Affiliation. Faculty Disclosures. Learning Objectives. Impact of HE on HRQOL. Overview of HE
Faculty Affiliation Strategies for Improving Long-term Management of Hepatic Encephalopathy: Assessing Therapies for Secondary Prophylaxis Alpesh Amin, MD Executive Director Hospitalist Program Professor
More informationNutrition Management of End- Stage Liver Failure
Nutrition Management of End- Stage Liver Failure Krystel Ouaijan, RDN, MSc Nutrition Support Dietitian in Saint George Hospital UMC PhD in University of Geneva Just few questions https://www.mentimeter.com/s/c1c1be18dc2
More informationLuis S. Marsano, MD Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Louisville and Louisville VAMC 2015
Luis S. Marsano, MD Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Louisville and Louisville VAMC 2015 Protein-calorie malnutrition (PCM) is extremely common
More informationIrritable bowel syndrome (IBS) is a functional gastrointestinal. Bacteria and the Role of Antibiotics in Irritable Bowel Syndrome INTRODUCTION
Bacteria and the Role of Antibiotics in Irritable Bowel Syndrome by Mark Pimentel Although several pathophysiologic models have been suggested, the etiology of irritable bowel syndrome (IBS) is unknown.
More informationDiagnosis and Management of Irritable Bowel Syndrome (IBS) For the Primary Care Provider
Diagnosis and Management of Irritable Bowel Syndrome (IBS) For the Primary Care Provider Elizabeth Coss, MD General Gastroenterologist Audie Murphy Veterans Hospital UT Health This presentation does not
More informationSpectrum of Diverticular Disease. Outline
Spectrum of Disease ACG Postgraduate Course January 24, 2015 Lisa Strate, MD, MPH Associate Professor of Medicine University of Washington, Seattle, WA Outline Traditional theories and updated perspectives
More informationAlice Fung, MD Oregon Health and Science University
Alice Fung, MD Oregon Health and Science University Disclosure Comments The speaker Alice Fung, MD Has relevant financial relationships to disclose. Received honorarium from (Guerbet). This individual
More informationHepatic encephalopathy (HE) is a neuropsychiatric
Considerations for the Cost-Effective Management of Hepatic Encephalopathy Steven L. Flamm, MD Hepatic encephalopathy (HE) is a neuropsychiatric condition that is usually associated with acute or chronic
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Rifaximin (Xifaxan) Reference Number: CP.PMN.47 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end
More informationSystematic review with multiple treatment comparison metaanalysis. on interventions for hepatic encephalopathy
Systematic review with multiple treatment comparison metaanalysis on interventions for hepatic encephalopathy Hepatic encephalopathy (HE) is a reversible neuropsychiatric syndrome associated with severe
More informationDavid Leff, DO. April 13, Disclosure. I have the following financial relationships to disclosure:
David Leff, DO AOMA 94 th Annual Convention April 13, 2016 Disclosure I have the following financial relationships to disclosure: Speaker s Bureau: Allergan Labs, Takeda Pharmaceutical, Valeant Pharmaceutical
More informationAbnormal Liver Chemistries. Lauren Myers, MMsc. PA-C Oregon Health and Science University
Abnormal Liver Chemistries Lauren Myers, MMsc. PA-C Oregon Health and Science University Disclosure 1. The speaker/planner Lauren Myers, MMSc, PA-C have no relevant financial relationships to disclose
More informationInnovative Therapeutics for Orphan Liver Disease
Innovative Therapeutics for Orphan Liver Disease Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements within the meaning of the Securities
More informationBiology of Hepatic Encephalopathy. School of Medicine Division of Transplantation Immunology & Mucosal Biology MRC Centre for Transplantation
Biology of Hepatic Encephalopathy School of Medicine Division of Transplantation Immunology & Mucosal Biology MRC Centre for Transplantation Pavlov s Physiology Factory 1904: Nobel Prize for developing
More informationPALLIATIVE CARE IN END-STAGE LIVER DISEASE
PALLIATIVE CARE IN END-STAGE LIVER DISEASE Ken S. Ota, DO Family Medicine Banner Good Samaritan Medical Center Learning Objectives: Describe the common bio-psycho-social issues in end-stage liver disease
More informationENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE
ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE The diagnosis of CDI should be based on a combination of clinical and laboratory findings. A case definition for the usual
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: rifaximin (Xifaxan) Reference Number: HIM.PA.68 Effective Date: 12/14 Last Review Date: 08/17 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important
More informationUse of transjugular intrahepatic portosystemic shunt in liver disease
Vol. XVIII No. 3 JOURNAL OF VASCULAR NURSING PAGE 83 Use of transjugular intrahepatic portosystemic shunt in liver disease Patricia Ann Radovich, RN, MSN, CCRN, FCCM Persons with cirrhosis have many complications.
More informationAll POOPed out: fecal microbiota transplant in C. difficile
All POOPed out: fecal microbiota transplant in C. difficile SUSAN M. KELLIE, MD, MPH PROFESSOR OF INTERNAL MEDICINE DIVISION OF INFECTIOUS DISEASES UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE HOSPITAL
More informationEach 5 ml contains lactulose 3.3 g, and lesser amounts of other sugars including lactose, galactose, tagatose and epilactose.
Actilax Lactulose PRODUCT INFORMATION Composition Each 5 ml contains lactulose 3.3 g, and lesser amounts of other sugars including lactose, galactose, tagatose and epilactose. Description Lactulose solution
More informationAntidiarrheals Antidiarrheal
Antidiarrheals Major factors in diarrhea Increased motility of the GI tract. Decreased absorption of fluid. Antidiarrheal drugs include: Antimotility agents. Adsorbents. Drugs that modify fluid and electrolyte
More informationLIVER CIRRHOSIS. The liver extracts nutrients from the blood and processes them for later use.
LIVER CIRRHOSIS William Sanchez, M.D. & Jayant A. Talwalkar, M.D., M.P.H. Advanced Liver Disease Study Group Miles and Shirley Fiterman Center for Digestive Diseases Mayo College of Medicine Rochester,
More informationStrategies for Improving Long-term Management of Hepatic Encephalopathy: Assessing Therapies for Secondary Prophylaxis
Strategies for Improving Long-term Management of Hepatic Encephalopathy: Assessing Therapies for Secondary Prophylaxis Sponsored by Integrity Continuing Education, Inc. Supported by an educational Practitioner
More informationIBS - Definition. Chronic functional disorder of GI generally characterized by:
IBS - Definition Chronic functional disorder of GI generally characterized by: 3500 3000 No. of Publications 2500 2000 1500 1000 Irritable Bowel syndrome Irritable Bowel Syndrome 500 0 1968-1977 1978-1987
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Accelerated intravascular coagulation and fibrinolysis (AICF) in liver disease, 390 391 Acid suppression in liver disease, 403 404 ACLF.
More informationChapter 5 Gastroenterology. Dose. Route. Units. Given. Dose. Route. Units. Given
Chapter 5 Gastroenterology Georgia Woodfield TERLIPRESSIN CIPROFLOXACIN 2 initial dose 500 Every 4 hours until bleeding controlled can be reduced to 1 after initial dose if side effects develop or if patient
More informationWhat s New in the Management of Hepatic Encephalopathy?
What s New in the Management of Hepatic Encephalopathy? Jasmohan S Bajaj, MD Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond,
More informationM0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR:
M0BCore Safety Profile Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg P-RMS: FR/H/PSUR/0066/001 Date of FAR: 26.11.2013 4.3 Contraindications Bromazepam must not be administered
More informationHEPATIC ENCEPHALOPATHY: PATHOGENESIS, DIAGNOSIS AND MANAGEMENT
Proc. R. Coll. Physicians Edinb. 1998; 28:111-118 HEPATIC ENCEPHALOPATHY: PATHOGENESIS, DIAGNOSIS AND MANAGEMENT H.F. Lui, R. Jalan, * P.C. Hayes, Centre for Liver and Digestive Disorders and Department
More informationASSESSMENT OF CEREBRAL VASCULAR RESISTANCE IN CIRRHOTIC PATIENTS WITH HEPATIC ENCEPHALOPATHY USING TRANSCRANIAL COLOR DOPPLER ULTRASONOGRAPHY
1 ASSESSMENT OF CEREBRAL VASCULAR RESISTANCE IN CIRRHOTIC PATIENTS WITH HEPATIC ENCEPHALOPATHY USING TRANSCRANIAL COLOR DOPPLER ULTRASONOGRAPHY Dissertation submitted in partial fulfillment of the requirements
More informationMarijuana and the Liver. Lauren Myers MMsc, PA-C
Marijuana and the Liver Lauren Myers MMsc, PA-C Disclosures 1. The speaker/planner Lauren Myers, MMSc, PA-C have no relevant financial relationships to disclose. 2. The planners, Atif Zaman, MD, MPH have
More informationXifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary
Xifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2 Lotronex (alosetron) a Indication For women with severe diarrheapredominant irritable
More informationChronic Hepatic Disease
Chronic Hepatic Disease 10 th Leading Cause of Death Liver Functions Energy Metabolism Protein Synthesis Solubilization, Transport, and Storage Protects and Clears drugs, damaged cells Causes of Liver
More informationSteps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV
Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,
More informationTreat primary. symptoms. Offer general lifestyle advice. Manage IBS according to the dominant symptom. Follow up. Symptoms do not improve
Treat primary symptoms Background information for clinicians Offer general lifestyle advice Background information for patients Manage IBS according to the dominant symptom Provenance Psychological symptoms
More informationCirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association
CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS
More informationPharmacology in Liver Disease. Sandeep Whitehead Advanced Clinical Pharmacist Hepatology and Liver Transplant
Pharmacology in Liver Disease Sandeep Whitehead Advanced Clinical Pharmacist Hepatology and Liver Transplant Objectives Outline the drug management for patients with: Ascites Spontaneous Bacterial Peritonitis
More informationIs one of the most common chronic disorders. causing patients to seek medical treatment.
ILOs After this lecture you should be able to : Define IBS Identify causes and risk factors of IBS Determine the appropriate therapeutic options for IBS Is one of the most common chronic disorders causing
More informationNeither activated charcoal nor whole bowel irrigation (WBI) is indicated in the routine management of acute or chronic lithium toxicity.
CRACKCast E160 Lithium Key concepts; The clinical pattern of acute and chronic toxicity is different. Gastrointestinal symptoms occur early and neurological toxicity manifest late in acute toxicity. Neurological
More informationOptimizing Outcomes of Patients Hospitalized for Hepatic Encephalopathy: Focus on Early Intervention and Transitional Care
Optimizing Outcomes of Patients Hospitalized for Hepatic Encephalopathy: Focus on Early Intervention and Transitional Care This CME activity is provided by Integrity Continuing Education. This CEU/CNE
More informationCONTROLLED DOCUMENT. Cirrhosis Care Bundle CATEGORY: Clinical Guidelines. CLASSIFICATION: Clinical. Controlled Document CG201 Number:
Cirrhosis Care Bundle CONTROLLED DOCUMENT CATEGORY: Clinical Guidelines CLASSIFICATION: Clinical Controlled Document CG201 Number: Version Number: 1 Controlled Document Clinical Guidelines Group Sponsor:
More informationManaging Encephalopathy in the Outpatient Setting
REVIEW Managing Encephalopathy in the Outpatient Setting Sahaj Rathi, M.D., and Radha K. Dhiman, M.D., D.M., F.A.M.S., F.A.C.G., F.R.C.P., F.A.A.S.L.D. Hepatic encephalopathy (HE) refers to brain dysfunction
More informationRMO Department Of Medicine, Malda Medical College, Malda 2. Assistant Professor, Department Of Community Medicine, Malda Medical College, Malda.
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 4 Ver. XIV (Apr. 2016), PP 45-49 www.iosrjournals.org A Comparative Study to Determine the
More informationIBS Irritable Bowel syndrome Therapeutics II PHCL 430
Salman Bin AbdulAziz University College Of Pharmacy IBS Irritable Bowel syndrome Therapeutics II PHCL 430 Email:- ahmedadel.pharmd@gmail.com Ahmed A AlAmer PharmD R.S is 32-year-old woman experiences intermittent
More informationRifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth
Aliment Pharmacol Ther 2005; 22: 31 35. doi: 10.1111/j.1365-2036.2005.02516.x Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth E. C. LAURITANO, M. GABRIELLI, A. LUPASCU,
More informationCirrhosis Patient Teaching Information
Cirrhosis Patient Teaching Information CIRRHOSIS What is Cirrhosis: Cirrhosis is the end stages of a liver disease. Over time, from years to decades, fibrosis (or scar tissue) progresses through stages
More informationReview Article Impact of Pretransplant Hepatic Encephalopathy on Liver Posttransplantation Outcomes
International Journal of Hepatology Volume 213, Article ID 952828, 9 pages http://dx.doi.org/1.1155/213/952828 Review Article Impact of Pretransplant Hepatic Encephalopathy on Liver Posttransplantation
More informationmore intense treatments are needed to get rid of the infection.
What Is Clostridium Difficile (C. Diff)? Clostridium difficile, or C. diff for short, is an infection from a bacterium that can grow in your intestines and cause bad GI symptoms. The main risk of getting
More information